Hypercoagulation in COVID-19 patients (search done on 28 March 2020)

Added June 15, 2020

Citation: Violi F, Pastori D, Cangemi R, et al. Hypercoagulation and antithrombotic treatment in coronavirus 2019: A new challenge. Thrombosis and haemostasis. 2020;120(6):949-56.

What is this? Some patients with COVID-19 will become critically ill and may present with hypercoagulation.

In this rapid review, the authors searched for clinical studies that assesses biological parameters hypercoagulation in COVID-19 patients. They restricted their searches to articles published in English and did the most recent search on 28 March 2020. They included 9 studies.

What was found: At the time of this review, the included studies showed that most patients with severe COVID-19 disease had increased levels of D-dimer, low levels of platelet count, prolonged prothrombin time, prolonged activated partial thromboplastin time and increasing transaminases values.


Disclaimer: This summary has been written by staff and volunteers of Evidence Aid in order to make the content of the original document accessible to decision makers who are searching for the available evidence on the coronavirus (COVID-19) but may not have the time, initially, to read the original report in full. This summary is not intended as a substitute for the medical advice of physicians, other health workers, professional associations, guideline developers, or national governments and international agencies. If readers of this summary think that the evidence that is presented within it is relevant to their decision-making they should refer to the content and details of the original article, and the advice and guidelines offered by other sources of expertise, before making decisions. Evidence Aid cannot be held responsible for any decisions made about the coronavirus (COVID-19) on the basis of this summary alone.